Propanc Biopharma, Inc. Overview
Pro stress-test →Propanc Biopharma is a development-stage biopharmaceutical healthcare company developing cancer treatments for patients with pancreatic, ovarian, and colorectal cancers. The company develops a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells.
Strategic Profile
Pro stress-test →The lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has research and collaboration agreements with the University of Jaén and University of Granada.
Competitive Landscape
Pro stress-test →Propanc competes in the oncology space against established companies and other biotech firms developing cancer immunotherapies and novel treatments. The market for pancreatic cancer treatments is substantial, but the company's pre-clinical stage positions it early in development relative to competitors with clinical data.
Industry Context
Propanc Biopharma, Inc. operates in Biopharmaceutical - Oncology.
Key facts
Founded: 2007 · Headquarters: Camberwell, Australia